Chatzisali, BeizaGaş, TolgaKılgın, HilmiAydemir, Kübra DuvanErümit, DilşatTopuz, Ruhan DenizUlugöl, Ahmet2021-11-202021-11-2020202148-47242548-0030https://dergipark.org.tr/tr/pub/tmsj/issue/52947/700217https://dergipark.org.tr/tr/download/article-file/997061https://hdl.handle.net/20.500.14551/6232Aims: It has been long suspected that the cannabinoid system participates in the antinociceptive effects of nonsteroidal anti-inflammatory drugs. We studied the possible effects of cannabinoid receptor antagonism on diclofenac-induced antinociceptionin the writhing test in mice. Methods: In our study, male BALB/c mice, weighing 20-30 g, were used. Writhing responses wereproduced by intraperitoneal injection of 0.6% acetic acid. Different doses of diclofenac (3, 10, 30 mg/kg, i.p.) were tested, thenthe influence of AM-251 (1 mg/kg, i.p.), a cannabinoid CB1 receptor antagonist and AM-630 (3 mg/kg, i.p.), a cannabinoidCB2 receptor antagonist on the antinociceptive effects of diclofenac was studied. Results: Diclofenac administration elicited asignificant, dose-dependent antinociceptive response; however, neither the cannabinoid CB1 receptor antagonist AM-251 northe cannabinoid CB2 receptor antagonist AM-630 had any influence on the antinociceptive effect of diclofenac. Conclusion:Iinhibition of cannabinoid receptors does not contribute to the antinociceptive action of systemic diclofenac. Further studiesare needed to explain the antinociceptive mechanism of diclofenac. Keywords: AM-251, AM-630, antinociception, cannabinoidreceptors, diclofenaceninfo:eu-repo/semantics/openAccessAM-251AM-630antinociceptioncannabinoid receptorsdiclofenacArticle7114700217